Protagonist Therapeutics Inc [PTGX] stock prices are up 1.04% to $54.38 at the moment. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The PTGX shares have gain 14.56% over the last week, with a monthly amount glided 26.20%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Protagonist Therapeutics Inc [NASDAQ: PTGX] stock has seen the most recent analyst activity on December 06, 2024, when Goldman initiated its Neutral rating and assigned the stock a price target of $47. Previously, BMO Capital Markets started tracking the stock with Outperform rating on December 06, 2024, and set its price target to $62. On November 05, 2024, Wedbush initiated with a Outperform rating and assigned a price target of $58 on the stock. TD Cowen started tracking the stock assigning a Buy rating and suggested a price target of $65 on September 24, 2024. Truist initiated its recommendation with a Buy and recommended $60 as its price target on September 09, 2024. CapitalOne started tracking with a Overweight rating for this stock on October 30, 2023, and assigned it a price target of $32.
The stock price of Protagonist Therapeutics Inc [PTGX] has been fluctuating between $30.67 and $60.60 over the past year. Currently, Wall Street analysts expect the stock to reach $73 within the next 12 months. Protagonist Therapeutics Inc [NASDAQ: PTGX] shares were valued at $54.38 at the most recent close of the market. An investor can expect a potential return of 34.24% based on the average PTGX price forecast.
Analyzing the PTGX fundamentals
The Protagonist Therapeutics Inc [NASDAQ:PTGX] reported sales of 207.80M for trailing twelve months, representing a drop of -88.89%. Gross Profit Margin for this corporation currently stands at 0.99% with Operating Profit Margin at 0.13%, Pretax Profit Margin comes in at 0.27%, and Net Profit Margin reading is 0.27%. To continue investigating profitability, this company’s Return on Assets is posted at 0.08, Equity is 0.09 and Total Capital is 0.04. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 53.33 points at the first support level, and at 52.28 for the second support level. However, for the 1st resistance point, the stock is sitting at 55.20, and for the 2nd resistance point, it is at 56.02.
Ratios To Look Out For
It’s worth pointing out that Protagonist Therapeutics Inc [NASDAQ:PTGX]’s Current Ratio is 17.26. Also, the Quick Ratio is 17.26, while the Cash Ratio stands at 3.98. Considering the valuation of this stock, the price to sales ratio is 16.22, the price to book ratio is 4.89 and price to earnings (TTM) ratio is 71.49.
Transactions by insiders
Recent insider trading involved Ali Asif, Chief Financial Officer, that happened on Apr 22 ’25 when 1756.0 shares were sold. Director, Waddill William D. completed a deal on Mar 17 ’25 to sell 4000.0 shares. Meanwhile, Director WILLIAM D WADDILL bought 4000.0 shares on Mar 17 ’25.
